Surgery Partners, Inc. $SGRY Stake Raised by AYAL Capital Advisors Ltd

AYAL Capital Advisors Ltd increased its holdings in Surgery Partners, Inc. (NASDAQ:SGRY) by 80.0% in the 4th quarter, Holdings Channel reports. The fund owned 225,000 shares of the company’s stock after purchasing an additional 100,000 shares during the period. Surgery Partners makes up about 1.2% of AYAL Capital Advisors Ltd’s portfolio, making the stock its 27th biggest position. AYAL Capital Advisors Ltd’s holdings in Surgery Partners were worth $3,476,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SGRY. Pentwater Capital Management LP increased its holdings in shares of Surgery Partners by 66.9% during the 3rd quarter. Pentwater Capital Management LP now owns 11,681,000 shares of the company’s stock valued at $252,777,000 after acquiring an additional 4,681,000 shares during the last quarter. UBS Group AG lifted its position in shares of Surgery Partners by 111.4% in the 4th quarter. UBS Group AG now owns 7,803,974 shares of the company’s stock worth $120,571,000 after acquiring an additional 4,113,052 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Surgery Partners by 528.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,959,686 shares of the company’s stock worth $30,277,000 after acquiring an additional 1,647,714 shares during the period. Glenview Capital Management LLC bought a new stake in shares of Surgery Partners in the 2nd quarter worth approximately $33,995,000. Finally, Dimensional Fund Advisors LP lifted its position in shares of Surgery Partners by 25.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 4,860,215 shares of the company’s stock worth $105,177,000 after acquiring an additional 988,956 shares during the period.

Analysts Set New Price Targets

Several research firms recently commented on SGRY. TD Cowen cut their target price on Surgery Partners from $28.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 5th. UBS Group restated a “buy” rating on shares of Surgery Partners in a research note on Wednesday, March 11th. Mizuho lowered their target price on Surgery Partners from $19.00 to $17.00 and set an “outperform” rating on the stock in a research note on Thursday, March 5th. Jefferies Financial Group reissued a “buy” rating and set a $17.00 price target on shares of Surgery Partners in a research report on Wednesday, May 6th. Finally, Benchmark reissued a “buy” rating on shares of Surgery Partners in a research report on Tuesday, March 3rd. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $22.18.

Surgery Partners Price Performance

SGRY stock opened at $14.23 on Thursday. The company has a market capitalization of $1.86 billion, a P/E ratio of -23.72, a price-to-earnings-growth ratio of 4.53 and a beta of 1.96. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.69 and a current ratio of 1.86. Surgery Partners, Inc. has a 52-week low of $11.41 and a 52-week high of $24.10. The business has a 50-day simple moving average of $13.90 and a two-hundred day simple moving average of $14.47.

Surgery Partners (NASDAQ:SGRY) last announced its earnings results on Tuesday, May 5th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.12. Surgery Partners had a positive return on equity of 1.04% and a negative net margin of 2.28%.The firm had revenue of $810.90 million for the quarter, compared to the consensus estimate of $797.69 million. During the same quarter in the previous year, the business earned $0.04 EPS. The company’s revenue was up 4.5% compared to the same quarter last year. Research analysts expect that Surgery Partners, Inc. will post 0.25 EPS for the current fiscal year.

Surgery Partners declared that its Board of Directors has initiated a stock repurchase program on Thursday, February 26th that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the company to purchase up to 9.7% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.